Balance Sheet Sarepta Therapeutics, Inc.

Equities

SRPT

US8036071004

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 02:30:00 14/02/2026 am IST			5-day change	1st Jan Change
17.79 ^USD	+2.24%		-3.84%	-17.33%

11/02	Sarepta Therapeutics to announce fourth quarter and full-year 2025 financial results	RE
04/02	Sarepta Therapeutics announces clinical trial application approval for SRP-1005 in Huntington's disease	RE

71fb0559c27af56f5a.0WLdvv9J32RwyyivOwYGLjNPqScQ6xqGyMXy3d8UPRo.mBDp2at9pgoinE-dDDJMQUYnm0ImhHbqmYO4i5F9VUinJ7P0y3qpDiqCTw

Published financial data: SAREPTA THERAPEUTICS, INC.

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: December	2020	2021	2022	2023	2024
Revenues	54Cr	70Cr	93Cr	124.33Cr	190.2Cr
Total Revenues	54Cr	70Cr	93Cr	124.33Cr	190.2Cr
Cost of Goods Sold, Total	79Cr	87Cr	101.11Cr	102.77Cr	112.36Cr
Gross Profit	-25Cr	-17Cr	-7.81Cr	22Cr	78Cr
Selling General & Admin Expenses, Total	32Cr	28Cr	45Cr	48Cr	56Cr
Amortization of Goodwill and Intangible Assets - (IS)	7L	7L	7L	15.59L	24.05L
Other Operating Expenses, Total	32Cr	28Cr	45Cr	48Cr	56Cr
Operating Income	-56Cr	-45Cr	-53Cr	-27Cr	22Cr
Interest Expense, Total	-5.99Cr	-6.35Cr	-5.32Cr	-2.2Cr	-1.84Cr
Interest And Investment Income	29.7L	4L	1.65Cr	3.63Cr	3.06Cr
Net Interest Expenses	-5.7Cr	-6.32Cr	-3.68Cr	1.42Cr	1.22Cr
Other Non Operating Income (Expenses)	5L	-9L	-69.21L	6L	-28.45L
EBT, Excl. Unusual Items	-62Cr	-51Cr	-57Cr	-25Cr	23Cr
Restructuring Charges	-	-	-	-	-
Gain (Loss) On Sale Of Investments	44.89L	-43.31L	86.6L	1.94Cr	4.11Cr
Gain (Loss) On Sale Of Assets	11Cr	10Cr	-	10Cr	-
Asset Writedown	-1L	-5L	-60L	-	-
In Process R&D Expenses	-	-	-	-	-
Legal Settlements	-	-	-	-	-
Other Unusual Items	-4.5Cr	-28L	-12Cr	-39Cr	-78.38L
EBT, Incl. Unusual Items	-55Cr	-42Cr	-69Cr	-52Cr	26Cr
Income Tax Expense	10.63L	-2L	1.35Cr	1.59Cr	2.55Cr
Earnings From Continuing Operations	-55Cr	-42Cr	-70Cr	-54Cr	24Cr
Net Income to Company	-55Cr	-42Cr	-70Cr	-54Cr	24Cr
Net Income - (IS)	-55Cr	-42Cr	-70Cr	-54Cr	24Cr
Net Income to Common Incl Extra Items	-55Cr	-42Cr	-70Cr	-54Cr	24Cr
Net Income to Common Excl. Extra Items	-55Cr	-42Cr	-70Cr	-54Cr	24Cr
Per Share Items
Net EPS - Basic	-7.11	-5.15	-8.03	-5.8	2.47
Basic EPS - Continuing Operations	-7.11	-5.15	-8.03	-5.8	2.47
Basic Weighted Average Shares Outstanding	7.8Cr	8.13Cr	8.76Cr	9.24Cr	9.51Cr
Net EPS - Diluted	-7.11	-5.15	-8.03	-5.8	2.34
Diluted EPS - Continuing Operations	-7.11	-5.15	-8.03	-5.8	2.34
Diluted Weighted Average Shares Outstanding	7.8Cr	8.13Cr	8.76Cr	9.24Cr	11Cr
Normalized Basic EPS	-4.97	-3.95	-4.1	-1.71	1.5
Normalized Diluted EPS	-4.97	-3.95	-4.1	-1.71	1.32
Supplemental Items
EBITDA	-54Cr	-41Cr	-49Cr	-22Cr	26Cr
EBITA	-56Cr	-45Cr	-53Cr	-27Cr	22Cr
EBIT	-56Cr	-45Cr	-53Cr	-27Cr	22Cr
EBITDAR	-50Cr	-36Cr	-43Cr	-16Cr	36Cr
Total Revenues (As Reported)	54Cr	70Cr	93Cr	124.33Cr	190.2Cr
Effective Tax Rate - (Ratio)	-0.19	0.04	-1.96	-3.05	9.79
Current Domestic Taxes	6L	-40T	1.32Cr	1.53Cr	2.48Cr
Current Foreign Taxes	7L	2L	9L	8L	10L
Total Current Taxes	13.08L	1L	1.41Cr	1.6Cr	2.58Cr
Deferred Domestic Taxes	-	-	-	-	-
Deferred Foreign Taxes	-2L	-3L	-6L	-2L	-2L
Total Deferred Taxes	-2L	-3L	-6L	-2L	-2L
Normalized Net Income	-39Cr	-32Cr	-36Cr	-16Cr	14Cr
Interest on Long-Term Debt	5.99Cr	6.35Cr	5.32Cr	2.2Cr	1.84Cr
Supplemental Operating Expense Items
Advertising Expense	-	-	-	2.86Cr	3.2Cr
Selling and Marketing Expenses	-	-	-	2.86Cr	3.2Cr
General and Administrative Expenses	-	-	-	-	-
Research And Development Expense From Footnotes	72Cr	77Cr	88Cr	88Cr	80Cr
Net Rental Expense, Total	3.6Cr	4.75Cr	5.37Cr	6.83Cr	10Cr
Imputed Operating Lease Interest Expense	1.9Cr	2.17Cr	1.66Cr	79.84L	1.12Cr
Imputed Operating Lease Depreciation	1.71Cr	2.58Cr	3.71Cr	6.04Cr	9.24Cr
Stock-Based Comp., COGS (Total)	4.17Cr	5.05Cr	6.13Cr	8.25Cr	7.4Cr
Stock-Based Comp., G&A Exp. (Total)	-	-	-	-	-
Stock-Based Comp., SG&A Exp. (Total)	6.64Cr	6.34Cr	17Cr	10Cr	11Cr
Stock-Based Comp., Other (Total)	-	-	-	-	-
Total Stock-Based Compensation	11Cr	11Cr	23Cr	18Cr	18Cr

Fiscal Period: December	2020	2021	2022	2023	2024
Assets
Cash And Equivalents	150.26Cr	211.59Cr	97Cr	43Cr	110.3Cr
Short Term Investments	44Cr	-	102.26Cr	124.78Cr	25Cr
Total Cash And Short Term Investments	193.86Cr	211.59Cr	198.94Cr	167.62Cr	135.48Cr
Accounts Receivable, Total	14Cr	17Cr	26Cr	43Cr	64Cr
Other Receivables	30.59L	-	33.11L	95.93L	1.31Cr
Total Receivables	14Cr	17Cr	26Cr	44Cr	65Cr
Inventory	23Cr	19Cr	20Cr	32Cr	75Cr
Prepaid Expenses	3.26Cr	2.95Cr	2.96Cr	3.02Cr	3.07Cr
Other Current Assets, Total	14Cr	10Cr	7.52Cr	11Cr	29Cr
Total Current Assets	248.52Cr	260.41Cr	255.79Cr	257.93Cr	307.35Cr
Gross Property Plant And Equipment	36Cr	35Cr	39Cr	55Cr	72Cr
Accumulated Depreciation	-7.6Cr	-11Cr	-15Cr	-19Cr	-23Cr
Net Property Plant And Equipment	28Cr	24Cr	24Cr	36Cr	49Cr
Long-term Investments	3.88Cr	3.49Cr	3.13Cr	65.27L	14Cr
Other Intangibles, Total	1.36Cr	1.42Cr	75.78L	2.96Cr	2.69Cr
Other Long-Term Assets, Total	16Cr	26Cr	29Cr	29Cr	24Cr
Total Assets	298.47Cr	314.8Cr	312.84Cr	326.46Cr	396.32Cr
Liabilities
Accounts Payable, Total	11Cr	7.67Cr	9.59Cr	16Cr	21Cr
Accrued Expenses, Total	14Cr	21Cr	34Cr	20Cr	24Cr
Current Portion of Long-Term Debt	-	-	-	11Cr	-
Current Portion of Leases	2.09Cr	1.5Cr	1.55Cr	1.78Cr	1.33Cr
Current Income Taxes Payable	-	-	1.25Cr	1.38Cr	1.74Cr
Unearned Revenue Current, Total	8.92Cr	8.92Cr	8.92Cr	5.04Cr	13Cr
Other Current Liabilities	5.23Cr	6.5Cr	7.08Cr	10Cr	11Cr
Total Current Liabilities	42Cr	45Cr	62Cr	65Cr	73Cr
Long-Term Debt	99Cr	109.69Cr	154.43Cr	113.25Cr	113.71Cr
Long-Term Leases	8.04Cr	4.15Cr	5.76Cr	14Cr	19Cr
Unearned Revenue Non Current	66Cr	57Cr	48Cr	44Cr	32Cr
Other Non Current Liabilities	7.06Cr	5.46Cr	3.69Cr	4.11Cr	4.92Cr
Total Liabilities	222.3Cr	222Cr	274.34Cr	240.52Cr	243.54Cr
Common Stock, Total	8T	9T	9T	9T	10T
Additional Paid In Capital	360.99Cr	413.48Cr	429.68Cr	530.46Cr	573.89Cr
Retained Earnings	-284.81Cr	-320.67Cr	-391.02Cr	-444.62Cr	-421.1Cr
Comprehensive Income and Other	3T	-20T	-16.64L	9L	-2L
Total Common Equity	76Cr	93Cr	38Cr	86Cr	152.77Cr
Total Equity	76Cr	93Cr	38Cr	86Cr	152.77Cr
Total Liabilities And Equity	298.47Cr	314.8Cr	312.84Cr	326.46Cr	396.32Cr
Supplemental Items
ECS Total Shares Outstanding on Filing Date	7.94Cr	8.71Cr	8.8Cr	9.39Cr	9.7Cr
ECS Total Common Shares Outstanding	7.94Cr	8.71Cr	8.8Cr	9.37Cr	9.69Cr
Book Value / Share	9.6	10.65	4.38	9.17	15.77
Tangible Book Value	75Cr	91Cr	38Cr	83Cr	150.09Cr
Tangible Book Value Per Share	9.43	10.49	4.29	8.85	15.49
Total Debt	109.38Cr	115.34Cr	161.74Cr	139.68Cr	134.29Cr
Net Debt	-84Cr	-96Cr	-37Cr	-28Cr	-1.19Cr
Debt Equivalent Oper. Leases	29Cr	38Cr	43Cr	55Cr	83Cr
Account Code - Inventory Valuation	5	5	5	5	5
Inventories - Raw Materials, Total	7.17Cr	-	-	-	-
Inventories - Work In Process, Total	14Cr	-	-	-	-
Inventories - Finished Goods, Total	2.05Cr	-	-	-	-
Land - (BS)	51.83L	51.83L	51.83L	51.83L	1.02Cr
Buildings, Total	3.94Cr	4.76Cr	4.79Cr	4.81Cr	5.12Cr
Machinery, Total	5.78Cr	7.5Cr	10Cr	12Cr	14Cr
Full Time Employees	866	840	1.16T	1.31T	1.37T

Fiscal Period: December	2020	2021	2022	2023	2024
Net Income	-55Cr	-42Cr	-70Cr	-54Cr	24Cr
Depreciation & Amortization - CF	2.56Cr	3.66Cr	4Cr	4.25Cr	3.5Cr
Amortization of Goodwill and Intangible Assets - (CF)	12.62L	13.06L	18.14L	19L	27L
Depreciation & Amortization, Total	2.69Cr	3.79Cr	4.18Cr	4.44Cr	3.77Cr
Amortization of Deferred Charges, Total - (CF)	-	1L	50T	-	-
(Gain) Loss From Sale Of Asset	-11Cr	-10Cr	1.08Cr	-10Cr	-
(Gain) Loss on Sale of Investments - (CF)	-21.86L	44.88L	25.75L	-1.59Cr	-
Asset Writedown & Restructuring Costs	-	-	-	-	-
Stock-Based Compensation (CF)	11Cr	11Cr	23Cr	18Cr	18Cr
Other Operating Activities, Total	8.28Cr	1.93Cr	13Cr	41Cr	5.36Cr
Change In Accounts Receivable	-1.05Cr	-5.16Cr	-6.16Cr	-19Cr	-20Cr
Change In Inventories	-6.06Cr	-8.38Cr	-5.08Cr	-15Cr	-40Cr
Change In Accounts Payable	4.2Cr	2.33Cr	15Cr	-5.01Cr	11Cr
Change in Unearned Revenues	75Cr	-8.92Cr	-8.92Cr	-8.68Cr	-3.22Cr
Change in Other Net Operating Assets	-17Cr	10Cr	1.46Cr	-1.07Cr	-20Cr
Cash from Operations	11Cr	-44Cr	-33Cr	-50Cr	-21Cr
Capital Expenditure	-8.22Cr	-3.85Cr	-3.08Cr	-7.61Cr	-14Cr
Cash Acquisitions	-	-	-	-	-
Sale (Purchase) of Intangible assets	11Cr	10Cr	-	9.08Cr	-1Cr
Investment in Marketable and Equity Securities, Total	-14Cr	44Cr	-101.36Cr	-18Cr	90Cr
Other Investing Activities, Total	-35L	-41.09L	-24.27L	-	-
Cash from Investing	-12Cr	50Cr	-104.69Cr	-17Cr	76Cr
Long-Term Debt Issued, Total	29Cr	-	112.74Cr	-	-
Total Debt Issued	29Cr	-	112.74Cr	-	-
Long-Term Debt Repaid, Total	-	-	-82Cr	-	-68T
Total Debt Repaid	-	-	-82Cr	-	-68T
Issuance of Common Stock	40Cr	57Cr	3Cr	5.12Cr	7.95Cr
Repurchase of Common Stock	-47.98L	-77.65L	-	-	-
Other Financing Activities, Total	-39T	-	-10Cr	7.38Cr	4.53Cr
Cash from Financing	68Cr	56Cr	23Cr	13Cr	12Cr
Net Change in Cash	67Cr	61Cr	-113.97Cr	-54Cr	67Cr
Supplemental Items
Cash Interest Paid	3.44Cr	5.59Cr	4.44Cr	1.59Cr	1.59Cr
Cash Income Tax Paid (Refund)	25.1L	6L	16.95L	1.51Cr	2.26Cr
Levered Free Cash Flow	-30Cr	-2.49Cr	-4.95Cr	-35Cr	-45Cr
Unlevered Free Cash Flow	-26Cr	1.48Cr	-1.62Cr	-33Cr	-43Cr
Change In Net Working Capital	7.21Cr	-8.01Cr	-7.11Cr	41Cr	65Cr
Net Debt Issued / Repaid	29Cr	-	30Cr	-	-68T

Fiscal Period: December	2020	2021	2022	2023	2024
Profitability
Return on Assets	-14.67	-9.16	-10.56	-5.24	3.77
Return on Total Capital	-20.72	-14.34	-16.29	-7.86	5.34
Return On Equity %	-70.15	-49.57	-107.16	-86.15	19.71
Return on Common Equity	-70.15	-49.57	-107.16	-86.15	19.71
Margin Analysis
Gross Profit Margin %	-45.46	-23.63	-8.37	17.34	40.92
SG&A Margin	58.85	40.27	48.38	38.76	29.33
EBITDA Margin %	-99.45	-58.6	-52.35	-17.97	13.45
EBITA Margin %	-104.2	-63.81	-56.63	-21.39	11.61
EBIT Margin %	-104.44	-64	-56.83	-21.54	11.47
Income From Continuing Operations Margin %	-102.6	-59.66	-75.4	-43.11	12.37
Net Income Margin %	-102.6	-59.66	-75.4	-43.11	12.37
Net Avail. For Common Margin %	-102.6	-59.66	-75.4	-43.11	12.37
Normalized Net Income Margin	-71.81	-45.71	-38.44	-12.72	7.48
Levered Free Cash Flow Margin	-55.78	-3.55	-5.3	-27.99	-23.42
Unlevered Free Cash Flow Margin	-48.85	2.1	-1.74	-26.88	-22.82
Asset Turnover
Asset Turnover	0.22	0.23	0.3	0.39	0.53
Fixed Assets Turnover	2.4	2.71	3.87	4.13	4.5
Receivables Turnover (Average Receivables)	4.77	4.57	4.36	3.62	3.57
Inventory Turnover (Average Inventory)	3.9	4.15	5.18	3.9	2.09
Short Term Liquidity
Current Ratio	5.97	5.75	4.13	3.95	4.2
Quick Ratio	4.99	5.05	3.63	3.24	2.74
Operating Cash Flow to Current Liabilities	0.26	-0.98	-0.53	-0.77	-0.28
Days Sales Outstanding (Average Receivables)	76.71	79.87	83.72	100.77	102.63
Days Outstanding Inventory (Average Inventory)	93.95	87.95	70.43	93.55	174.73
Average Days Payable Outstanding	38.75	41.7	30.62	41.51	44.77
Cash Conversion Cycle (Average Days)	131.91	126.11	123.53	152.81	232.59
Long Term Solvency
Total Debt/Equity	143.59	124.29	420.15	162.54	87.9
Total Debt / Total Capital	58.95	55.42	80.77	61.91	46.78
LT Debt/Equity	140.84	122.67	416.12	148.19	87.03
Long-Term Debt / Total Capital	57.82	54.69	80	56.44	46.32
Total Liabilities / Total Assets	74.48	70.52	87.69	73.68	61.45
EBIT / Interest Expense	-9.41	-7.07	-9.96	-12.17	11.86
EBITDA / Interest Expense	-8.36	-5.73	-8.16	-7.05	19.54
(EBITDA - Capex) / Interest Expense	-9.73	-6.33	-8.74	-10.5	12.1
Total Debt / EBITDA	-2.18	-3.17	-3.72	-9.01	3.74
Net Debt / EBITDA	1.69	2.65	0.86	1.8	-0.03
Total Debt / (EBITDA - Capex)	-1.88	-2.87	-3.47	-6.04	6.04
Net Debt / (EBITDA - Capex)	1.45	2.39	0.8	1.21	-0.05
Growth Over Prior Year
Total Revenues, 1 Yr. Growth %	41.82	29.96	32.93	33.26	52.97
Gross Profit, 1 Yr. Growth %	3.83	-32.45	-52.93	-356.47	261.01
EBITDA, 1 Yr. Growth %	7.85	-23.49	18.74	-54.8	-214.49
EBITA, 1 Yr. Growth %	8.05	-20.42	17.97	-50.23	-183.02
EBIT, 1 Yr. Growth %	8.03	-20.36	18.03	-50.05	-181.43
Earnings From Cont. Operations, 1 Yr. Growth %	-22.51	-24.43	67.98	-23.81	-143.89
Net Income, 1 Yr. Growth %	-22.51	-24.43	67.98	-23.81	-143.89
Normalized Net Income, 1 Yr. Growth %	13.69	-17.28	11.8	-56.38	-189.93
Diluted EPS Before Extra, 1 Yr. Growth %	-26.8	-27.52	55.9	-27.8	-140.31
Accounts Receivable, 1 Yr. Growth %	49.13	26.65	49.38	67.76	48.01
Inventory, 1 Yr. Growth %	35.35	-19.72	9.54	58.29	132.29
Net Property, Plant and Equip., 1 Yr. Growth %	68.42	-16.13	3.51	45.76	36.84
Total Assets, 1 Yr. Growth %	63.74	5.47	-0.62	4.35	21.4
Tangible Book Value, 1 Yr. Growth %	-7.14	22.14	-58.7	119.87	80.89
Common Equity, 1 Yr. Growth %	-6.9	21.82	-58.52	123.23	77.78
Cash From Operations, 1 Yr. Growth %	-123.54	-512.38	-26.59	53.99	-58.92
Capital Expenditures, 1 Yr. Growth %	37.85	-53.18	-19.92	146.9	79.95
Levered Free Cash Flow, 1 Yr. Growth %	-0.51	-91.11	400.36	536.71	34.95
Unlevered Free Cash Flow, 1 Yr. Growth %	-7	-106.08	-154.31	1.46T	37.18
Compound Annual Growth Rate Over Two Years
Total Revenues, 2 Yr. CAGR %	33.95	35.76	31.43	33.09	42.78
Gross Profit, 2 Yr. CAGR %	34.91	-16.25	-43.61	16	204.28
EBITDA, 2 Yr. CAGR %	27.23	-9.13	-4.69	-25.78	-28.06
EBITA, 2 Yr. CAGR %	28.29	-7.27	-3.11	-22.45	-35.72
EBIT, 2 Yr. CAGR %	28.14	-7.24	-3.05	-22.3	-36.23
Earnings From Cont. Operations, 2 Yr. CAGR %	23.74	-23.47	12.67	13.13	-42.17
Net Income, 2 Yr. CAGR %	23.74	-23.47	12.67	13.13	-42.17
Normalized Net Income, 2 Yr. CAGR %	29.31	-3.02	-3.83	-29.41	-37.37
Diluted EPS Before Extra, 2 Yr. CAGR %	14.08	-27.16	6.3	6.09	-46.05
Accounts Receivable, 2 Yr. CAGR %	66.23	37.43	37.54	58.3	57.57
Inventory, 2 Yr. CAGR %	35.98	4.24	-6.23	31.67	91.75
Net Property, Plant and Equip., 2 Yr. CAGR %	70.54	18.85	-6.82	22.83	41.23
Total Assets, 2 Yr. CAGR %	34.82	31.41	2.38	1.84	12.55
Tangible Book Value, 2 Yr. CAGR %	-14.39	6.5	-28.98	-4.71	99.43
Common Equity, 2 Yr. CAGR %	-14.1	6.5	-28.91	-3.77	99.22
Cash From Operations, 2 Yr. CAGR %	-47.42	-1.47	74	6.32	-20.47
Capital Expenditures, 2 Yr. CAGR %	15.94	-19.66	-38.76	40.62	110.79
Levered Free Cash Flow, 2 Yr. CAGR %	10.73	-71.3	-57.99	532.55	185.51
Unlevered Free Cash Flow, 2 Yr. CAGR %	8.37	-77.18	-74.18	228.3	350.65
Compound Annual Growth Rate Over Three Years
Total Revenues, 3 Yr. CAGR %	51.74	32.6	34.81	32.04	39.42
Gross Profit, 3 Yr. CAGR %	18.59	7.13	-30.89	-4.24	69.36
EBITDA, 3 Yr. CAGR %	58.63	7.42	-0.65	-25.37	-14.24
EBITA, 3 Yr. CAGR %	58.64	9.41	0.48	-22.11	-20.67
EBIT, 3 Yr. CAGR %	58.15	9.35	0.51	-21.99	-21.08
Earnings From Cont. Operations, 3 Yr. CAGR %	121.94	4.98	-0.54	-1.1	-17.49
Net Income, 3 Yr. CAGR %	121.94	4.98	-0.54	-1.1	-17.49
Normalized Net Income, 3 Yr. CAGR %	61.98	11.42	1.69	-25.85	-23.48
Diluted EPS Before Extra, 3 Yr. CAGR %	102.07	-1.93	-6.13	-6.56	-23.16
Accounts Receivable, 3 Yr. CAGR %	66.3	51.82	41.3	46.96	54.79
Inventory, 3 Yr. CAGR %	40.52	14.07	5.97	11.65	59.1
Net Property, Plant and Equip., 3 Yr. CAGR %	87	34.62	13.5	8.16	27.33
Total Assets, 3 Yr. CAGR %	31.65	24.23	19.73	3.03	7.98
Tangible Book Value, 3 Yr. CAGR %	-1.16	-3.62	-22.34	3.51	17.99
Common Equity, 3 Yr. CAGR %	-1.17	-3.49	-22.22	4.1	18.08
Cash From Operations, 3 Yr. CAGR %	-22.63	4.47	-10.67	67.05	-22.56
Capital Expenditures, 3 Yr. CAGR %	89.92	-14.3	-19.74	-2.54	52.67
Levered Free Cash Flow, 3 Yr. CAGR %	122.03	-53.36	-45.33	7.47	271.39
Unlevered Free Cash Flow, 3 Yr. CAGR %	122.66	-59.64	-61.5	11.22	140.99
Compound Annual Growth Rate Over Five Years
Total Revenues, 5 Yr. CAGR %	236.44	164.51	43.27	32.8	37.94
Gross Profit, 5 Yr. CAGR %	11.12	-1.69	-11.92	9.83	26.91
EBITDA, 5 Yr. CAGR %	21.18	9.93	29.41	-7.61	-12.48
EBITA, 5 Yr. CAGR %	21.76	11.39	30.25	-4.91	-15.77
EBIT, 5 Yr. CAGR %	21.76	11.4	30.03	-4.86	-16.02
Earnings From Cont. Operations, 5 Yr. CAGR %	20.29	9.4	69.23	8.17	-19.94
Net Income, 5 Yr. CAGR %	20.29	9.4	69.23	8.17	-19.94
Normalized Net Income, 5 Yr. CAGR %	24.12	14.37	31.49	-7.38	-16.06
Diluted EPS Before Extra, 5 Yr. CAGR %	6.44	-1.26	56.28	1.21	-24.79
Accounts Receivable, 5 Yr. CAGR %	102.53	101.03	54.14	54.38	47.6
Inventory, 5 Yr. CAGR %	-	70.79	19.53	20.81	34.34
Net Property, Plant and Equip., 5 Yr. CAGR %	49.85	44.32	41.52	29.77	23.87
Total Assets, 5 Yr. CAGR %	61.25	49.32	19.05	14.73	16.8
Tangible Book Value, 5 Yr. CAGR %	32.43	22.7	-13.4	-4.06	13.25
Common Equity, 5 Yr. CAGR %	31.96	22.48	-13.38	-3.6	13.3
Cash From Operations, 5 Yr. CAGR %	-6.38	12.51	7	5.21	-14.73
Capital Expenditures, 5 Yr. CAGR %	89.08	48.44	20.77	4.47	18.09
Levered Free Cash Flow, 5 Yr. CAGR %	32.03	-29.99	12.44	7.21	8.02
Unlevered Free Cash Flow, 5 Yr. CAGR %	28.87	-36.85	-7.49	8.27	8.88